Lucid Diagnostics Inc (LUCD NASDAQ) stock market data APIs
$0.9539
0.01(1%)
as of May 19, 2026
Try our APIs with
free plan!
Lucid Diagnostics Inc Financial Data Overview
Price chart is built with
Anychart
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Prev. Close
0.9539
Open
0.9655
High
1.019
Low
0.9415
52 wk Range
0.9424-1.7
Market Cap
183 M
Shares Outstanding
191 M
Revenue
5 134 K
EPS
-0.07
Beta
1.104
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Lucid Diagnostics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lucid Diagnostics Inc data using free add-ons & libraries
Get Lucid Diagnostics Inc Fundamental Data
Lucid Diagnostics Inc Fundamental data includes:
- Net Revenue: 5 134 K
- EBITDA: -48 394 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: -0.0633
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lucid Diagnostics Inc News
New
Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary
Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Operational Context Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how y...
LUCD Q1 2026 Earnings Transcript
Image source: The Motley Fool. DATE Thursday, May 14, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Lishan Aklog, M.D. Chief Financial Officer — Dennis McGrath ...
Lucid Diagnostics Q1 Earnings Call Highlights
Key Points Interested in Lucid Diagnostics Inc.? Here are five stocks we like better. Lucid Diagnostics reported Q1 2026 EsoGuard test volume of 3,177 and revenue of $1.3 million, with volume still a...
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.88 per share a year ago. These figures are...
Get Lucid Diagnostics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
